...
首页> 外文期刊>The Journal of dermatology >Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40
【24h】

Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40

机译:PITERIASISIS rubra Pilaris在白细胞介素-17a阻滞后进展到广义红霉蛋白,但在白细胞介素-12 / 23 p40封闭后改善

获取原文
获取原文并翻译 | 示例
           

摘要

We report herein a case of a 72-year-old man with pityriasis rubra pilaris (PRP) that was refractory to conventional therapies. His skin lesions progressed to generalized erythroderma despite anti-interleukin (IL)-17A antibody therapy. Topical corticosteroids, emollients, systemic retinoid, methotrexate, cyclosporin and phototherapy yielded no therapeutic response. However, blockade of IL-12/23 p40 dramatically improved his cutaneous lesions. Complete remission was achieved 4 weeks after the first injection of ustekinumab and maintained for more than 48 weeks. Our data indicate that IL-12 was associated with the onset of PRP in this patient, rather than IL-23. IL-12 is critical for the differentiation of T-helper (Th)1 cells. Thus, the Th1 pathway may be associated with the onset of PRP.
机译:我们在本文中报告了一个72岁男性患有悲观的鲁革毒性(PRP),对常规治疗难以难治。 尽管抗白细胞介素(IL)-17A抗体治疗,他的皮肤病变进展到广义红霉蛋白。 局部皮质类固醇,润肤剂,全身类视黄醇,甲氨蝶呤,环孢菌素和光疗产生没有治疗反应。 然而,阻断IL-12/23 P40显着改善了他的皮肤病变。 在第一次注射Ustekinumab后4周达到完全缓解,并保持超过48周。 我们的数据表明IL-12与本患者中PRP的发作相关,而不是IL-23。 IL-12对于T-辅助(TH)1细胞的分化至关重要。 因此,TH1路径可以与PRP的开始相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号